Department of Biological Sciences, Louisiana State University, Baton Rouge, LA 70803, USA.
Future Med Chem. 2010 Jan;2(1):93-119. doi: 10.4155/fmc.09.149.
Bacterial ribosomal RNA is the target of clinically important antibiotics, while biologically important RNAs in viral and eukaryotic genomes present a range of potential drug targets. The physicochemical properties of RNA present difficulties for medicinal chemistry, particularly when oral availability is needed. Peptidic ligands and analysis of their RNA-binding properties are providing insight into RNA recognition. RNA-binding ligands include far more chemical classes than just aminoglycosides. Chemical functionalities from known RNA-binding small molecules are being exploited in fragment- and ligand-based projects. While targeting of RNA for drug design is very challenging, continuing advances in our understanding of the principles of RNA-ligand interaction will be necessary to realize the full potential of this class of targets.
细菌核糖体 RNA 是临床重要抗生素的靶标,而病毒和真核基因组中具有生物学意义的 RNA 则呈现出一系列潜在的药物靶标。RNA 的理化性质给药物化学带来了困难,特别是当需要口服可用性时。肽配体及其 RNA 结合特性的分析为 RNA 识别提供了深入了解。与 RNA 结合的配体包括的化学类群远不止氨基糖苷类。在基于片段和基于配体的项目中,正在利用已知 RNA 结合小分子的化学官能团。虽然针对 RNA 进行药物设计极具挑战性,但要充分发挥这一类靶标的潜力,就必须不断深入了解 RNA-配体相互作用的原理。